Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corcept TherapeuticsHAM:HTD -4.78%86 Owner Earnings per Share (TTM) is 0.31 as of Mar. 2026, which is 99% below its 10-year median of 30.10. GuruFocus rates HAM:HTD with a GF Score™ of 86/100 and a GF Value™ of €52.76. The stock has 8 warning signs investors should review. Among 207 Biotechnology companies, Corcept Therapeutics ranks worse than 93.72% on this metric.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Corcept Therapeutics's Owner Earnings per Share (TTM) ended in Mar. 2026 was €0.31. It's Price-to-Owner-Earnings ratio for today is 242.97.
The historical rank and industry rank for Corcept Therapeutics's Owner Earnings per Share (TTM) or its related term are showing as below:
HAM:HTD'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.39 Med: 30.1 Max: 721.11
Current: 244.51
Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.
Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.
Corcept Therapeutics Owner Earnings per Share (TTM) Related Terms
Corcept Therapeutics Owner Earnings per Share (TTM) Historical Data
* Premium members only.
The historical data trend for Corcept Therapeutics's Owner Earnings per Share (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics Owner Earnings per Share (TTM) Chart
HAM:HTD vs PRAX, IBRX, NUVL: Owner Earnings per Share (TTM) Comparison
For the Biotechnology subindustry, Corcept Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics Price-to-Owner-Earnings vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's Price-to-Owner-Earnings falls into.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income.
Corcept Therapeutics's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2026 was €-31.9 Mil.
4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = €0.3 Mil
It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.
The following shows how to get maintenance capital expenditure.
First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.
Corcept Therapeutics's 5-Year Average Maintenance Capital Expenditure = €0.3 Mil
5. "Change In Working Capital" is from cashflow statement. Corcept Therapeutics's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2026 was €22.8 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Owner Earnings per Share (TTM) of 0.31 mean?
Corcept Therapeutics (HAM:HTD) has a Owner Earnings per Share (TTM) of 0.31 as of Mar. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Corcept Therapeutics. This is 99% below median its historical median of 30.10. Over the past decade, Corcept Therapeutics' Owner Earnings per Share (TTM) has ranged from 8.39 to 721.11. According to the industry distribution chart, Corcept Therapeutics ranks #194 out of 207 companies in the Biotechnology industry, placing it in the top 93.7%.
Is Corcept Therapeutics' Owner Earnings per Share (TTM) too high?
Corcept Therapeutics' current Owner Earnings per Share (TTM) of 0.31 is 99% below median its 10-year median of 30.10. Over the past 10 years, this metric has ranged from a low of 8.39 to a high of 721.11. The Biotechnology industry median Owner Earnings per Share (TTM) is 24.86. Corcept Therapeutics' value of 0.31 is 98.8% below this industry median. Based on the distribution chart, Corcept Therapeutics ranks #194 out of 207 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Corcept Therapeutics has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Owner Earnings per Share (TTM) compare to PRAX and IBRX?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #194 out of 207 companies for Owner Earnings per Share (TTM). This places Corcept Therapeutics in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 24.86. Corcept Therapeutics' value of 0.31 is 98.8% below this benchmark. Historically, Corcept Therapeutics' own Owner Earnings per Share (TTM) has ranged from 8.39 to 721.11 over the past decade. While the company's 10-year median is 30.10 vs. the industry median of 24.86, Corcept Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Biotechnology company?
The median Owner Earnings per Share (TTM) among Biotechnology companies is 24.86, based on 207 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corcept Therapeutics's current Owner Earnings per Share (TTM) of 0.31 is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Corcept Therapeutics. For the Biotechnology industry, the median Owner Earnings per Share (TTM) is 24.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corcept Therapeutics's current Owner Earnings per Share (TTM) is 0.31, which is 99% below median its own 10-year median of 30.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Corcept Therapeutics (HAM:HTD) has a current Owner Earnings per Share (TTM) of 0.31. The stock's GF Value™ is €52.76, compared to a current price of €75.32 — trading 42.8% above its estimated fair value. The current Owner Earnings per Share (TTM) is 0.31, which is 99% below median its 10-year median of 30.10 and 98.8% below the Biotechnology industry median of 24.86. Corcept Therapeutics' overall GF Score™ is 86/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Corcept Therapeutics (HAM:HTD), the current Owner Earnings per Share (TTM) is 0.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (HAM:HTD) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of €75.32 is trading 42.8% above its estimated GF Value™ of €52.76.
Key valuation signals for HAM:HTD:
Owner Earnings per Share (TTM): 0.31 (99% below median its 10-year median of 30.10)
GF Value™: €52.76 vs. price of €75.32 (42.8% above fair value)
Industry Position: 98.8% below the Biotechnology median (#194 of 207)
No single metric tells the full story. See the HAM:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
86GF Score
Get the complete analysis for HAM:HTD
Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:HTD has been successfully added to your 
